nodes	percent_of_prediction	percent_of_DWPC	metapath
Alitretinoin—peripheral nervous system neoplasm—bone cancer	0.793	1	CtDrD
Alitretinoin—RXRG—a6b1 and a6b4 Integrin signaling—MST1R—bone cancer	0.0045	0.0562	CbGpPWpGaD
Alitretinoin—RXRB—a6b1 and a6b4 Integrin signaling—MST1R—bone cancer	0.00423	0.0529	CbGpPWpGaD
Alitretinoin—RXRA—a6b1 and a6b4 Integrin signaling—MST1R—bone cancer	0.0022	0.0276	CbGpPWpGaD
Alitretinoin—RARG—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.00208	0.026	CbGpPWpGaD
Alitretinoin—CRABP1—The citric acid (TCA) cycle and respiratory electron transport—NDUFA12—bone cancer	0.00196	0.0245	CbGpPWpGaD
Alitretinoin—CRABP2—The citric acid (TCA) cycle and respiratory electron transport—NDUFA12—bone cancer	0.00196	0.0245	CbGpPWpGaD
Alitretinoin—RARG—Nuclear Receptors—NR1I2—bone cancer	0.00191	0.0238	CbGpPWpGaD
Alitretinoin—RARB—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.00187	0.0234	CbGpPWpGaD
Alitretinoin—RARA—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.00179	0.0224	CbGpPWpGaD
Alitretinoin—RXRG—Nuclear Receptors—NR1I2—bone cancer	0.00174	0.0218	CbGpPWpGaD
Alitretinoin—RARB—Nuclear Receptors—NR1I2—bone cancer	0.00171	0.0214	CbGpPWpGaD
Alitretinoin—CYP1A2—Lidocaine metabolism—CYP3A4—bone cancer	0.00168	0.021	CbGpPWpGaD
Alitretinoin—RXRB—Nuclear Receptors—NR1I2—bone cancer	0.00164	0.0205	CbGpPWpGaD
Alitretinoin—RARA—Nuclear Receptors—NR1I2—bone cancer	0.00164	0.0205	CbGpPWpGaD
Alitretinoin—RARG—Nuclear Receptor transcription pathway—NR1I2—bone cancer	0.00151	0.0188	CbGpPWpGaD
Alitretinoin—RXRA—Liver X Receptor Pathway—CYP3A4—bone cancer	0.00145	0.0182	CbGpPWpGaD
Alitretinoin—RXRG—Nuclear Receptor transcription pathway—NR1I2—bone cancer	0.00138	0.0172	CbGpPWpGaD
Alitretinoin—RARB—Nuclear Receptor transcription pathway—NR1I2—bone cancer	0.00135	0.0169	CbGpPWpGaD
Alitretinoin—RARA—Nuclear Receptor transcription pathway—NR1I2—bone cancer	0.00129	0.0162	CbGpPWpGaD
Alitretinoin—RXRB—Nuclear Receptor transcription pathway—NR1I2—bone cancer	0.00129	0.0162	CbGpPWpGaD
Alitretinoin—RARG—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.00122	0.0152	CbGpPWpGaD
Alitretinoin—RARB—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.00109	0.0137	CbGpPWpGaD
Alitretinoin—RARA—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.00105	0.0131	CbGpPWpGaD
Alitretinoin—RXRA—Farnesoid X Receptor  Pathway—CYP3A4—bone cancer	0.000869	0.0109	CbGpPWpGaD
Alitretinoin—RXRA—Nuclear Receptors—NR1I2—bone cancer	0.000854	0.0107	CbGpPWpGaD
Alitretinoin—RARG—Generic Transcription Pathway—ZNF77—bone cancer	0.000768	0.00961	CbGpPWpGaD
Alitretinoin—RXRG—Generic Transcription Pathway—ZNF77—bone cancer	0.000703	0.00879	CbGpPWpGaD
Alitretinoin—ABCB1—Codeine and Morphine Metabolism—CYP3A4—bone cancer	0.000693	0.00867	CbGpPWpGaD
Alitretinoin—RARB—Generic Transcription Pathway—ZNF77—bone cancer	0.000689	0.00862	CbGpPWpGaD
Alitretinoin—RXRA—Nuclear Receptor transcription pathway—NR1I2—bone cancer	0.000675	0.00844	CbGpPWpGaD
Alitretinoin—RARA—Generic Transcription Pathway—ZNF77—bone cancer	0.000661	0.00826	CbGpPWpGaD
Alitretinoin—RXRB—Generic Transcription Pathway—ZNF77—bone cancer	0.000661	0.00826	CbGpPWpGaD
Alitretinoin—ABCB1—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.000649	0.00812	CbGpPWpGaD
Alitretinoin—ABCB1—HIF-1-alpha transcription factor network—CITED2—bone cancer	0.000648	0.00811	CbGpPWpGaD
Alitretinoin—CYP1A2—Aflatoxin B1 metabolism—CYP3A4—bone cancer	0.000616	0.0077	CbGpPWpGaD
Alitretinoin—RXRA—The citric acid (TCA) cycle and respiratory electron transport—NDUFA12—bone cancer	0.000592	0.00741	CbGpPWpGaD
Alitretinoin—RXRA—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000572	0.00716	CbGpPWpGaD
Alitretinoin—RXRG—a6b1 and a6b4 Integrin signaling—MET—bone cancer	0.000551	0.0069	CbGpPWpGaD
Alitretinoin—CYP1A2—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000551	0.00689	CbGpPWpGaD
Alitretinoin—RXRB—a6b1 and a6b4 Integrin signaling—MET—bone cancer	0.000518	0.00648	CbGpPWpGaD
Alitretinoin—RXRA—Orphan transporters—TUBB4B—bone cancer	0.000468	0.00586	CbGpPWpGaD
Alitretinoin—RXRA—PPAR Alpha Pathway—CDK4—bone cancer	0.000419	0.00524	CbGpPWpGaD
Alitretinoin—RXRA—Orphan transporters—TUBB2A—bone cancer	0.000404	0.00505	CbGpPWpGaD
Alitretinoin—RARB—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	0.000389	0.00487	CbGpPWpGaD
Alitretinoin—ABCB1—Drug Induction of Bile Acid Pathway—CYP3A4—bone cancer	0.000379	0.00475	CbGpPWpGaD
Alitretinoin—RARA—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	0.000373	0.00467	CbGpPWpGaD
Alitretinoin—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000373	0.00467	CbGpPWpGaD
Alitretinoin—RARG—Gene Expression—ZNF77—bone cancer	0.00037	0.00463	CbGpPWpGaD
Alitretinoin—RXRG—Regulation of Androgen receptor activity—MDM2—bone cancer	0.000359	0.00449	CbGpPWpGaD
Alitretinoin—RXRA—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000346	0.00433	CbGpPWpGaD
Alitretinoin—RXRA—Generic Transcription Pathway—ZNF77—bone cancer	0.000344	0.00431	CbGpPWpGaD
Alitretinoin—RXRG—Gene Expression—ZNF77—bone cancer	0.000338	0.00423	CbGpPWpGaD
Alitretinoin—RXRB—Regulation of Androgen receptor activity—MDM2—bone cancer	0.000337	0.00422	CbGpPWpGaD
Alitretinoin—RARB—Gene Expression—ZNF77—bone cancer	0.000332	0.00415	CbGpPWpGaD
Alitretinoin—RARB—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	0.000331	0.00414	CbGpPWpGaD
Alitretinoin—RARA—Gene Expression—ZNF77—bone cancer	0.000318	0.00398	CbGpPWpGaD
Alitretinoin—RXRB—Gene Expression—ZNF77—bone cancer	0.000318	0.00398	CbGpPWpGaD
Alitretinoin—CYP1A2—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.000318	0.00398	CbGpPWpGaD
Alitretinoin—RARA—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	0.000317	0.00397	CbGpPWpGaD
Alitretinoin—RXRG—Regulation of Androgen receptor activity—JUN—bone cancer	0.000312	0.0039	CbGpPWpGaD
Alitretinoin—RARB—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	0.000301	0.00377	CbGpPWpGaD
Alitretinoin—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000298	0.00372	CbGpPWpGaD
Alitretinoin—CRABP1—Metabolism—NDUFA12—bone cancer	0.000295	0.00369	CbGpPWpGaD
Alitretinoin—CRABP2—Metabolism—NDUFA12—bone cancer	0.000295	0.00369	CbGpPWpGaD
Alitretinoin—RXRB—Regulation of Androgen receptor activity—JUN—bone cancer	0.000293	0.00367	CbGpPWpGaD
Alitretinoin—CYP1A2—Estrogen metabolism—CYP3A4—bone cancer	0.000289	0.00362	CbGpPWpGaD
Alitretinoin—RARA—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	0.000289	0.00361	CbGpPWpGaD
Alitretinoin—RXRA—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000281	0.00351	CbGpPWpGaD
Alitretinoin—RXRG—a6b1 and a6b4 Integrin signaling—EGFR—bone cancer	0.000279	0.00349	CbGpPWpGaD
Alitretinoin—CYP1A2—Aflatoxin activation and detoxification—CYP3A4—bone cancer	0.000277	0.00347	CbGpPWpGaD
Alitretinoin—RARB—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	0.000274	0.00343	CbGpPWpGaD
Alitretinoin—RARB—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	0.000271	0.00338	CbGpPWpGaD
Alitretinoin—RXRA—a6b1 and a6b4 Integrin signaling—MET—bone cancer	0.00027	0.00338	CbGpPWpGaD
Alitretinoin—CYP1A2—Xenobiotics—CYP3A4—bone cancer	0.000266	0.00333	CbGpPWpGaD
Alitretinoin—RARA—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	0.000263	0.00329	CbGpPWpGaD
Alitretinoin—RXRB—a6b1 and a6b4 Integrin signaling—EGFR—bone cancer	0.000263	0.00328	CbGpPWpGaD
Alitretinoin—RARG—Generic Transcription Pathway—NR1I2—bone cancer	0.00026	0.00325	CbGpPWpGaD
Alitretinoin—RARA—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	0.000259	0.00325	CbGpPWpGaD
Alitretinoin—CYP1A2—Tamoxifen metabolism—CYP3A4—bone cancer	0.000256	0.0032	CbGpPWpGaD
Alitretinoin—CRABP1—Metabolism—NT5C3A—bone cancer	0.000245	0.00306	CbGpPWpGaD
Alitretinoin—CRABP2—Metabolism—NT5C3A—bone cancer	0.000245	0.00306	CbGpPWpGaD
Alitretinoin—RXRG—Generic Transcription Pathway—NR1I2—bone cancer	0.000238	0.00298	CbGpPWpGaD
Alitretinoin—CYP1A2—Metapathway biotransformation—CYP4V2—bone cancer	0.000237	0.00297	CbGpPWpGaD
Alitretinoin—RARB—Generic Transcription Pathway—NR1I2—bone cancer	0.000233	0.00292	CbGpPWpGaD
Alitretinoin—RARB—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	0.000229	0.00287	CbGpPWpGaD
Alitretinoin—ABCB1—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000229	0.00286	CbGpPWpGaD
Alitretinoin—RARA—Generic Transcription Pathway—NR1I2—bone cancer	0.000224	0.0028	CbGpPWpGaD
Alitretinoin—RXRB—Generic Transcription Pathway—NR1I2—bone cancer	0.000224	0.0028	CbGpPWpGaD
Alitretinoin—RARA—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	0.00022	0.00275	CbGpPWpGaD
Alitretinoin—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000218	0.00273	CbGpPWpGaD
Alitretinoin—RXRG—Adipogenesis—RB1—bone cancer	0.000205	0.00257	CbGpPWpGaD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	0.000194	0.00243	CbGpPWpGaD
Alitretinoin—RARA—Adipogenesis—RB1—bone cancer	0.000193	0.00241	CbGpPWpGaD
Alitretinoin—RARG—Gene Expression—FUS—bone cancer	0.000181	0.00226	CbGpPWpGaD
Alitretinoin—RXRA—Transcriptional regulation of white adipocyte differentiation—CDK4—bone cancer	0.000176	0.0022	CbGpPWpGaD
Alitretinoin—RXRA—Regulation of Androgen receptor activity—MDM2—bone cancer	0.000176	0.0022	CbGpPWpGaD
Alitretinoin—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000174	0.00218	CbGpPWpGaD
Alitretinoin—RARB—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	0.00017	0.00213	CbGpPWpGaD
Alitretinoin—RXRA—Gene Expression—ZNF77—bone cancer	0.000166	0.00207	CbGpPWpGaD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	0.000165	0.00207	CbGpPWpGaD
Alitretinoin—RXRG—Gene Expression—FUS—bone cancer	0.000165	0.00207	CbGpPWpGaD
Alitretinoin—RARA—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	0.000163	0.00204	CbGpPWpGaD
Alitretinoin—RARB—Gene Expression—FUS—bone cancer	0.000162	0.00203	CbGpPWpGaD
Alitretinoin—RXRB—Gene Expression—FUS—bone cancer	0.000155	0.00194	CbGpPWpGaD
Alitretinoin—RARA—Gene Expression—FUS—bone cancer	0.000155	0.00194	CbGpPWpGaD
Alitretinoin—RXRA—Regulation of Androgen receptor activity—JUN—bone cancer	0.000153	0.00191	CbGpPWpGaD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	0.000151	0.00188	CbGpPWpGaD
Alitretinoin—CYP1A2—Estrogen Receptor Pathway—JUN—bone cancer	0.00015	0.00188	CbGpPWpGaD
Alitretinoin—RXRA—Biological oxidations—CYP3A4—bone cancer	0.000149	0.00186	CbGpPWpGaD
Alitretinoin—RXRA—NRF2 pathway—GSTP1—bone cancer	0.000145	0.00182	CbGpPWpGaD
Alitretinoin—RXRA—NRF2 pathway—TGFBR2—bone cancer	0.000145	0.00182	CbGpPWpGaD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	0.000137	0.00171	CbGpPWpGaD
Alitretinoin—RXRA—a6b1 and a6b4 Integrin signaling—EGFR—bone cancer	0.000137	0.00171	CbGpPWpGaD
Alitretinoin—CYP1A2—Tryptophan metabolism—CYP3A4—bone cancer	0.000137	0.00171	CbGpPWpGaD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	0.000135	0.00169	CbGpPWpGaD
Alitretinoin—RXRA—Biological oxidations—GSTP1—bone cancer	0.000127	0.00159	CbGpPWpGaD
Alitretinoin—RARB—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	0.000126	0.00158	CbGpPWpGaD
Alitretinoin—RARG—Gene Expression—NR1I2—bone cancer	0.000125	0.00157	CbGpPWpGaD
Alitretinoin—RARB—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	0.000122	0.00152	CbGpPWpGaD
Alitretinoin—RARA—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	0.000121	0.00151	CbGpPWpGaD
Alitretinoin—RXRA—Generic Transcription Pathway—NR1I2—bone cancer	0.000117	0.00146	CbGpPWpGaD
Alitretinoin—RARA—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	0.000117	0.00146	CbGpPWpGaD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	0.000115	0.00143	CbGpPWpGaD
Alitretinoin—RXRG—Gene Expression—NR1I2—bone cancer	0.000115	0.00143	CbGpPWpGaD
Alitretinoin—RXRA—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000114	0.00143	CbGpPWpGaD
Alitretinoin—RARB—Gene Expression—NR1I2—bone cancer	0.000112	0.0014	CbGpPWpGaD
Alitretinoin—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.00011	0.00138	CbGpPWpGaD
Alitretinoin—RARB—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	0.00011	0.00137	CbGpPWpGaD
Alitretinoin—CYP1A2—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000109	0.00136	CbGpPWpGaD
Alitretinoin—RARA—Gene Expression—NR1I2—bone cancer	0.000108	0.00135	CbGpPWpGaD
Alitretinoin—RXRB—Gene Expression—NR1I2—bone cancer	0.000108	0.00135	CbGpPWpGaD
Alitretinoin—CRABP1—Metabolism—ENO2—bone cancer	0.000107	0.00134	CbGpPWpGaD
Alitretinoin—CRABP2—Metabolism—ENO2—bone cancer	0.000107	0.00134	CbGpPWpGaD
Alitretinoin—RARA—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	0.000105	0.00131	CbGpPWpGaD
Alitretinoin—RXRA—Adipogenesis—RB1—bone cancer	0.000101	0.00126	CbGpPWpGaD
Alitretinoin—CRABP1—Metabolism—DHFR—bone cancer	9.94e-05	0.00124	CbGpPWpGaD
Alitretinoin—CRABP2—Metabolism—DHFR—bone cancer	9.94e-05	0.00124	CbGpPWpGaD
Alitretinoin—RXRA—Transmembrane transport of small molecules—TUBB2A—bone cancer	9.86e-05	0.00123	CbGpPWpGaD
Alitretinoin—Sweating—Epirubicin—bone cancer	9.58e-05	0.000755	CcSEcCtD
Alitretinoin—Pollakiuria—Doxorubicin—bone cancer	9.58e-05	0.000755	CcSEcCtD
Alitretinoin—Haematuria—Epirubicin—bone cancer	9.53e-05	0.000751	CcSEcCtD
Alitretinoin—Pharyngitis—Methotrexate—bone cancer	9.52e-05	0.00075	CcSEcCtD
Alitretinoin—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—bone cancer	9.49e-05	0.00119	CbGpPWpGaD
Alitretinoin—Urinary tract disorder—Methotrexate—bone cancer	9.47e-05	0.000746	CcSEcCtD
Alitretinoin—Photosensitivity reaction—Doxorubicin—bone cancer	9.47e-05	0.000746	CcSEcCtD
Alitretinoin—Weight increased—Doxorubicin—bone cancer	9.44e-05	0.000744	CcSEcCtD
Alitretinoin—Epistaxis—Epirubicin—bone cancer	9.43e-05	0.000743	CcSEcCtD
Alitretinoin—Urethral disorder—Methotrexate—bone cancer	9.4e-05	0.000741	CcSEcCtD
Alitretinoin—Weight decreased—Doxorubicin—bone cancer	9.38e-05	0.00074	CcSEcCtD
Alitretinoin—Sinusitis—Epirubicin—bone cancer	9.38e-05	0.000739	CcSEcCtD
Alitretinoin—Agranulocytosis—Epirubicin—bone cancer	9.33e-05	0.000735	CcSEcCtD
Alitretinoin—Pneumonia—Doxorubicin—bone cancer	9.3e-05	0.000733	CcSEcCtD
Alitretinoin—CRABP1—Metabolism—GNA11—bone cancer	9.29e-05	0.00116	CbGpPWpGaD
Alitretinoin—CRABP2—Metabolism—GNA11—bone cancer	9.29e-05	0.00116	CbGpPWpGaD
Alitretinoin—Infestation—Doxorubicin—bone cancer	9.25e-05	0.000729	CcSEcCtD
Alitretinoin—Infestation NOS—Doxorubicin—bone cancer	9.25e-05	0.000729	CcSEcCtD
Alitretinoin—Drowsiness—Doxorubicin—bone cancer	9.25e-05	0.000729	CcSEcCtD
Alitretinoin—RARG—Gene Expression—EIF2S1—bone cancer	9.25e-05	0.00116	CbGpPWpGaD
Alitretinoin—Visual impairment—Methotrexate—bone cancer	9.24e-05	0.000728	CcSEcCtD
Alitretinoin—Stevens-Johnson syndrome—Doxorubicin—bone cancer	9.17e-05	0.000723	CcSEcCtD
Alitretinoin—Hypersensitivity—Cisplatin—bone cancer	9.15e-05	0.000721	CcSEcCtD
Alitretinoin—Renal failure—Doxorubicin—bone cancer	9.09e-05	0.000717	CcSEcCtD
Alitretinoin—Erythema multiforme—Methotrexate—bone cancer	9.06e-05	0.000715	CcSEcCtD
Alitretinoin—Neuropathy peripheral—Doxorubicin—bone cancer	9.06e-05	0.000715	CcSEcCtD
Alitretinoin—Haemoglobin—Epirubicin—bone cancer	9.02e-05	0.000711	CcSEcCtD
Alitretinoin—Stomatitis—Doxorubicin—bone cancer	9.01e-05	0.000711	CcSEcCtD
Alitretinoin—Urinary tract infection—Doxorubicin—bone cancer	8.99e-05	0.000709	CcSEcCtD
Alitretinoin—Conjunctivitis—Doxorubicin—bone cancer	8.99e-05	0.000709	CcSEcCtD
Alitretinoin—Hepatitis—Epirubicin—bone cancer	8.97e-05	0.000707	CcSEcCtD
Alitretinoin—Haemorrhage—Epirubicin—bone cancer	8.97e-05	0.000707	CcSEcCtD
Alitretinoin—Eye disorder—Methotrexate—bone cancer	8.96e-05	0.000706	CcSEcCtD
Alitretinoin—CYP1A2—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	8.95e-05	0.00112	CbGpPWpGaD
Alitretinoin—Tinnitus—Methotrexate—bone cancer	8.94e-05	0.000705	CcSEcCtD
Alitretinoin—RXRA—Metabolism—NDUFA12—bone cancer	8.93e-05	0.00112	CbGpPWpGaD
Alitretinoin—Hypoaesthesia—Epirubicin—bone cancer	8.93e-05	0.000704	CcSEcCtD
Alitretinoin—Asthenia—Cisplatin—bone cancer	8.91e-05	0.000702	CcSEcCtD
Alitretinoin—Pharyngitis—Epirubicin—bone cancer	8.9e-05	0.000702	CcSEcCtD
Alitretinoin—Sweating—Doxorubicin—bone cancer	8.87e-05	0.000699	CcSEcCtD
Alitretinoin—Urinary tract disorder—Epirubicin—bone cancer	8.86e-05	0.000698	CcSEcCtD
Alitretinoin—Oedema peripheral—Epirubicin—bone cancer	8.84e-05	0.000697	CcSEcCtD
Alitretinoin—Haematuria—Doxorubicin—bone cancer	8.82e-05	0.000695	CcSEcCtD
Alitretinoin—Urethral disorder—Epirubicin—bone cancer	8.8e-05	0.000693	CcSEcCtD
Alitretinoin—Epistaxis—Doxorubicin—bone cancer	8.72e-05	0.000688	CcSEcCtD
Alitretinoin—Angiopathy—Methotrexate—bone cancer	8.7e-05	0.000686	CcSEcCtD
Alitretinoin—Sinusitis—Doxorubicin—bone cancer	8.68e-05	0.000684	CcSEcCtD
Alitretinoin—Visual impairment—Epirubicin—bone cancer	8.65e-05	0.000682	CcSEcCtD
Alitretinoin—Agranulocytosis—Doxorubicin—bone cancer	8.63e-05	0.00068	CcSEcCtD
Alitretinoin—RARB—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	8.62e-05	0.00108	CbGpPWpGaD
Alitretinoin—Chills—Methotrexate—bone cancer	8.6e-05	0.000678	CcSEcCtD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	8.5e-05	0.00106	CbGpPWpGaD
Alitretinoin—Diarrhoea—Cisplatin—bone cancer	8.49e-05	0.000669	CcSEcCtD
Alitretinoin—Erythema multiforme—Epirubicin—bone cancer	8.48e-05	0.000669	CcSEcCtD
Alitretinoin—Alopecia—Methotrexate—bone cancer	8.47e-05	0.000668	CcSEcCtD
Alitretinoin—RXRG—Gene Expression—EIF2S1—bone cancer	8.46e-05	0.00106	CbGpPWpGaD
Alitretinoin—CRABP2—Metabolism—CYP3A4—bone cancer	8.42e-05	0.00105	CbGpPWpGaD
Alitretinoin—CRABP1—Metabolism—CYP3A4—bone cancer	8.42e-05	0.00105	CbGpPWpGaD
Alitretinoin—Mental disorder—Methotrexate—bone cancer	8.4e-05	0.000662	CcSEcCtD
Alitretinoin—Eye disorder—Epirubicin—bone cancer	8.38e-05	0.000661	CcSEcCtD
Alitretinoin—CRABP1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	8.38e-05	0.00105	CbGpPWpGaD
Alitretinoin—CRABP2—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	8.38e-05	0.00105	CbGpPWpGaD
Alitretinoin—Tinnitus—Epirubicin—bone cancer	8.37e-05	0.000659	CcSEcCtD
Alitretinoin—Malnutrition—Methotrexate—bone cancer	8.35e-05	0.000658	CcSEcCtD
Alitretinoin—Erythema—Methotrexate—bone cancer	8.35e-05	0.000658	CcSEcCtD
Alitretinoin—Haemoglobin—Doxorubicin—bone cancer	8.34e-05	0.000658	CcSEcCtD
Alitretinoin—Flushing—Epirubicin—bone cancer	8.33e-05	0.000656	CcSEcCtD
Alitretinoin—Haemorrhage—Doxorubicin—bone cancer	8.3e-05	0.000654	CcSEcCtD
Alitretinoin—Hepatitis—Doxorubicin—bone cancer	8.3e-05	0.000654	CcSEcCtD
Alitretinoin—RARB—Gene Expression—EIF2S1—bone cancer	8.29e-05	0.00104	CbGpPWpGaD
Alitretinoin—RARA—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	8.26e-05	0.00103	CbGpPWpGaD
Alitretinoin—Hypoaesthesia—Doxorubicin—bone cancer	8.26e-05	0.000651	CcSEcCtD
Alitretinoin—Pharyngitis—Doxorubicin—bone cancer	8.24e-05	0.000649	CcSEcCtD
Alitretinoin—Urinary tract disorder—Doxorubicin—bone cancer	8.2e-05	0.000646	CcSEcCtD
Alitretinoin—Oedema peripheral—Doxorubicin—bone cancer	8.18e-05	0.000645	CcSEcCtD
Alitretinoin—Angiopathy—Epirubicin—bone cancer	8.14e-05	0.000642	CcSEcCtD
Alitretinoin—Urethral disorder—Doxorubicin—bone cancer	8.14e-05	0.000641	CcSEcCtD
Alitretinoin—RXRA—Gene Expression—FUS—bone cancer	8.1e-05	0.00101	CbGpPWpGaD
Alitretinoin—Back pain—Methotrexate—bone cancer	8.07e-05	0.000636	CcSEcCtD
Alitretinoin—Chills—Epirubicin—bone cancer	8.05e-05	0.000635	CcSEcCtD
Alitretinoin—RARG—Gene Expression—EZH2—bone cancer	8.03e-05	0.001	CbGpPWpGaD
Alitretinoin—Arrhythmia—Epirubicin—bone cancer	8.02e-05	0.000632	CcSEcCtD
Alitretinoin—Visual impairment—Doxorubicin—bone cancer	8e-05	0.000631	CcSEcCtD
Alitretinoin—RARA—Gene Expression—EIF2S1—bone cancer	7.95e-05	0.000995	CbGpPWpGaD
Alitretinoin—RXRB—Gene Expression—EIF2S1—bone cancer	7.95e-05	0.000995	CbGpPWpGaD
Alitretinoin—Alopecia—Epirubicin—bone cancer	7.93e-05	0.000625	CcSEcCtD
Alitretinoin—Vomiting—Cisplatin—bone cancer	7.89e-05	0.000622	CcSEcCtD
Alitretinoin—Vision blurred—Methotrexate—bone cancer	7.87e-05	0.00062	CcSEcCtD
Alitretinoin—Mental disorder—Epirubicin—bone cancer	7.86e-05	0.00062	CcSEcCtD
Alitretinoin—Erythema multiforme—Doxorubicin—bone cancer	7.85e-05	0.000619	CcSEcCtD
Alitretinoin—Rash—Cisplatin—bone cancer	7.83e-05	0.000617	CcSEcCtD
Alitretinoin—Dermatitis—Cisplatin—bone cancer	7.82e-05	0.000616	CcSEcCtD
Alitretinoin—Malnutrition—Epirubicin—bone cancer	7.81e-05	0.000616	CcSEcCtD
Alitretinoin—Erythema—Epirubicin—bone cancer	7.81e-05	0.000616	CcSEcCtD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	7.77e-05	0.000972	CbGpPWpGaD
Alitretinoin—Eye disorder—Doxorubicin—bone cancer	7.76e-05	0.000612	CcSEcCtD
Alitretinoin—Ill-defined disorder—Methotrexate—bone cancer	7.74e-05	0.00061	CcSEcCtD
Alitretinoin—Tinnitus—Doxorubicin—bone cancer	7.74e-05	0.00061	CcSEcCtD
Alitretinoin—Anaemia—Methotrexate—bone cancer	7.71e-05	0.000608	CcSEcCtD
Alitretinoin—Flushing—Doxorubicin—bone cancer	7.7e-05	0.000607	CcSEcCtD
Alitretinoin—Flatulence—Epirubicin—bone cancer	7.7e-05	0.000607	CcSEcCtD
Alitretinoin—Tension—Epirubicin—bone cancer	7.66e-05	0.000604	CcSEcCtD
Alitretinoin—Nervousness—Epirubicin—bone cancer	7.59e-05	0.000598	CcSEcCtD
Alitretinoin—Back pain—Epirubicin—bone cancer	7.55e-05	0.000595	CcSEcCtD
Alitretinoin—Angiopathy—Doxorubicin—bone cancer	7.53e-05	0.000594	CcSEcCtD
Alitretinoin—Malaise—Methotrexate—bone cancer	7.53e-05	0.000593	CcSEcCtD
Alitretinoin—Chills—Doxorubicin—bone cancer	7.45e-05	0.000587	CcSEcCtD
Alitretinoin—Arrhythmia—Doxorubicin—bone cancer	7.42e-05	0.000585	CcSEcCtD
Alitretinoin—RXRA—Metabolism—NT5C3A—bone cancer	7.4e-05	0.000926	CbGpPWpGaD
Alitretinoin—Nausea—Cisplatin—bone cancer	7.37e-05	0.000581	CcSEcCtD
Alitretinoin—CYP1A2—Aryl Hydrocarbon Receptor—RB1—bone cancer	7.36e-05	0.000921	CbGpPWpGaD
Alitretinoin—Vision blurred—Epirubicin—bone cancer	7.36e-05	0.00058	CcSEcCtD
Alitretinoin—RXRG—Gene Expression—EZH2—bone cancer	7.35e-05	0.000919	CbGpPWpGaD
Alitretinoin—Alopecia—Doxorubicin—bone cancer	7.34e-05	0.000578	CcSEcCtD
Alitretinoin—Cough—Methotrexate—bone cancer	7.28e-05	0.000574	CcSEcCtD
Alitretinoin—Mental disorder—Doxorubicin—bone cancer	7.27e-05	0.000573	CcSEcCtD
Alitretinoin—Ill-defined disorder—Epirubicin—bone cancer	7.25e-05	0.000571	CcSEcCtD
Alitretinoin—RARB—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	7.23e-05	0.000905	CbGpPWpGaD
Alitretinoin—Convulsion—Methotrexate—bone cancer	7.23e-05	0.00057	CcSEcCtD
Alitretinoin—Erythema—Doxorubicin—bone cancer	7.23e-05	0.00057	CcSEcCtD
Alitretinoin—Malnutrition—Doxorubicin—bone cancer	7.23e-05	0.00057	CcSEcCtD
Alitretinoin—Anaemia—Epirubicin—bone cancer	7.22e-05	0.000569	CcSEcCtD
Alitretinoin—RARB—Gene Expression—EZH2—bone cancer	7.21e-05	0.000901	CbGpPWpGaD
Alitretinoin—CRABP1—Metabolism—GSTP1—bone cancer	7.2e-05	0.000901	CbGpPWpGaD
Alitretinoin—CRABP2—Metabolism—GSTP1—bone cancer	7.2e-05	0.000901	CbGpPWpGaD
Alitretinoin—Agitation—Epirubicin—bone cancer	7.18e-05	0.000566	CcSEcCtD
Alitretinoin—Flatulence—Doxorubicin—bone cancer	7.12e-05	0.000561	CcSEcCtD
Alitretinoin—Myalgia—Methotrexate—bone cancer	7.11e-05	0.00056	CcSEcCtD
Alitretinoin—Chest pain—Methotrexate—bone cancer	7.11e-05	0.00056	CcSEcCtD
Alitretinoin—Arthralgia—Methotrexate—bone cancer	7.11e-05	0.00056	CcSEcCtD
Alitretinoin—Tension—Doxorubicin—bone cancer	7.09e-05	0.000559	CcSEcCtD
Alitretinoin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	7.06e-05	0.000556	CcSEcCtD
Alitretinoin—Malaise—Epirubicin—bone cancer	7.04e-05	0.000555	CcSEcCtD
Alitretinoin—Discomfort—Methotrexate—bone cancer	7.02e-05	0.000553	CcSEcCtD
Alitretinoin—Nervousness—Doxorubicin—bone cancer	7.02e-05	0.000553	CcSEcCtD
Alitretinoin—Syncope—Epirubicin—bone cancer	7e-05	0.000552	CcSEcCtD
Alitretinoin—Back pain—Doxorubicin—bone cancer	6.99e-05	0.000551	CcSEcCtD
Alitretinoin—CYP1A2—Phase II conjugation—GSTP1—bone cancer	6.95e-05	0.00087	CbGpPWpGaD
Alitretinoin—RARA—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	6.94e-05	0.000868	CbGpPWpGaD
Alitretinoin—RXRB—Gene Expression—EZH2—bone cancer	6.91e-05	0.000864	CbGpPWpGaD
Alitretinoin—RARA—Gene Expression—EZH2—bone cancer	6.91e-05	0.000864	CbGpPWpGaD
Alitretinoin—Palpitations—Epirubicin—bone cancer	6.9e-05	0.000544	CcSEcCtD
Alitretinoin—Confusional state—Methotrexate—bone cancer	6.87e-05	0.000541	CcSEcCtD
Alitretinoin—Loss of consciousness—Epirubicin—bone cancer	6.86e-05	0.000541	CcSEcCtD
Alitretinoin—Cough—Epirubicin—bone cancer	6.82e-05	0.000537	CcSEcCtD
Alitretinoin—Anaphylactic shock—Methotrexate—bone cancer	6.81e-05	0.000537	CcSEcCtD
Alitretinoin—Vision blurred—Doxorubicin—bone cancer	6.81e-05	0.000537	CcSEcCtD
Alitretinoin—Convulsion—Epirubicin—bone cancer	6.77e-05	0.000533	CcSEcCtD
Alitretinoin—Infection—Methotrexate—bone cancer	6.77e-05	0.000533	CcSEcCtD
Alitretinoin—Hypertension—Epirubicin—bone cancer	6.74e-05	0.000532	CcSEcCtD
Alitretinoin—Ill-defined disorder—Doxorubicin—bone cancer	6.71e-05	0.000529	CcSEcCtD
Alitretinoin—Nervous system disorder—Methotrexate—bone cancer	6.68e-05	0.000527	CcSEcCtD
Alitretinoin—Anaemia—Doxorubicin—bone cancer	6.68e-05	0.000526	CcSEcCtD
Alitretinoin—Thrombocytopenia—Methotrexate—bone cancer	6.67e-05	0.000526	CcSEcCtD
Alitretinoin—Chest pain—Epirubicin—bone cancer	6.65e-05	0.000524	CcSEcCtD
Alitretinoin—Arthralgia—Epirubicin—bone cancer	6.65e-05	0.000524	CcSEcCtD
Alitretinoin—Myalgia—Epirubicin—bone cancer	6.65e-05	0.000524	CcSEcCtD
Alitretinoin—Agitation—Doxorubicin—bone cancer	6.64e-05	0.000523	CcSEcCtD
Alitretinoin—Anxiety—Epirubicin—bone cancer	6.63e-05	0.000522	CcSEcCtD
Alitretinoin—Skin disorder—Methotrexate—bone cancer	6.62e-05	0.000521	CcSEcCtD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	6.61e-05	0.000826	CbGpPWpGaD
Alitretinoin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	6.6e-05	0.000521	CcSEcCtD
Alitretinoin—Hyperhidrosis—Methotrexate—bone cancer	6.58e-05	0.000519	CcSEcCtD
Alitretinoin—Discomfort—Epirubicin—bone cancer	6.57e-05	0.000518	CcSEcCtD
Alitretinoin—Malaise—Doxorubicin—bone cancer	6.52e-05	0.000514	CcSEcCtD
Alitretinoin—Dry mouth—Epirubicin—bone cancer	6.5e-05	0.000513	CcSEcCtD
Alitretinoin—Anorexia—Methotrexate—bone cancer	6.49e-05	0.000512	CcSEcCtD
Alitretinoin—Syncope—Doxorubicin—bone cancer	6.48e-05	0.000511	CcSEcCtD
Alitretinoin—Confusional state—Epirubicin—bone cancer	6.43e-05	0.000507	CcSEcCtD
Alitretinoin—Palpitations—Doxorubicin—bone cancer	6.39e-05	0.000503	CcSEcCtD
Alitretinoin—Anaphylactic shock—Epirubicin—bone cancer	6.37e-05	0.000502	CcSEcCtD
Alitretinoin—Oedema—Epirubicin—bone cancer	6.37e-05	0.000502	CcSEcCtD
Alitretinoin—Hypotension—Methotrexate—bone cancer	6.36e-05	0.000502	CcSEcCtD
Alitretinoin—Loss of consciousness—Doxorubicin—bone cancer	6.35e-05	0.000501	CcSEcCtD
Alitretinoin—Infection—Epirubicin—bone cancer	6.33e-05	0.000499	CcSEcCtD
Alitretinoin—Cough—Doxorubicin—bone cancer	6.31e-05	0.000497	CcSEcCtD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	6.3e-05	0.000788	CbGpPWpGaD
Alitretinoin—CYP1A2—Tryptophan metabolism—MDM2—bone cancer	6.28e-05	0.000785	CbGpPWpGaD
Alitretinoin—Shock—Epirubicin—bone cancer	6.27e-05	0.000494	CcSEcCtD
Alitretinoin—Convulsion—Doxorubicin—bone cancer	6.26e-05	0.000494	CcSEcCtD
Alitretinoin—Nervous system disorder—Epirubicin—bone cancer	6.25e-05	0.000493	CcSEcCtD
Alitretinoin—Thrombocytopenia—Epirubicin—bone cancer	6.24e-05	0.000492	CcSEcCtD
Alitretinoin—Hypertension—Doxorubicin—bone cancer	6.24e-05	0.000492	CcSEcCtD
Alitretinoin—Tachycardia—Epirubicin—bone cancer	6.22e-05	0.00049	CcSEcCtD
Alitretinoin—Musculoskeletal discomfort—Methotrexate—bone cancer	6.21e-05	0.000489	CcSEcCtD
Alitretinoin—Skin disorder—Epirubicin—bone cancer	6.19e-05	0.000488	CcSEcCtD
Alitretinoin—Hyperhidrosis—Epirubicin—bone cancer	6.16e-05	0.000486	CcSEcCtD
Alitretinoin—Insomnia—Methotrexate—bone cancer	6.16e-05	0.000486	CcSEcCtD
Alitretinoin—Chest pain—Doxorubicin—bone cancer	6.15e-05	0.000485	CcSEcCtD
Alitretinoin—Arthralgia—Doxorubicin—bone cancer	6.15e-05	0.000485	CcSEcCtD
Alitretinoin—Myalgia—Doxorubicin—bone cancer	6.15e-05	0.000485	CcSEcCtD
Alitretinoin—Anxiety—Doxorubicin—bone cancer	6.13e-05	0.000483	CcSEcCtD
Alitretinoin—Paraesthesia—Methotrexate—bone cancer	6.12e-05	0.000482	CcSEcCtD
Alitretinoin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	6.11e-05	0.000482	CcSEcCtD
Alitretinoin—Discomfort—Doxorubicin—bone cancer	6.08e-05	0.000479	CcSEcCtD
Alitretinoin—Anorexia—Epirubicin—bone cancer	6.08e-05	0.000479	CcSEcCtD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	6.07e-05	0.00076	CbGpPWpGaD
Alitretinoin—Dyspnoea—Methotrexate—bone cancer	6.07e-05	0.000479	CcSEcCtD
Alitretinoin—Somnolence—Methotrexate—bone cancer	6.06e-05	0.000477	CcSEcCtD
Alitretinoin—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—bone cancer	6.05e-05	0.000757	CbGpPWpGaD
Alitretinoin—Dry mouth—Doxorubicin—bone cancer	6.02e-05	0.000474	CcSEcCtD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	6.02e-05	0.000752	CbGpPWpGaD
Alitretinoin—Dyspepsia—Methotrexate—bone cancer	6e-05	0.000473	CcSEcCtD
Alitretinoin—Hypotension—Epirubicin—bone cancer	5.96e-05	0.000469	CcSEcCtD
Alitretinoin—Confusional state—Doxorubicin—bone cancer	5.95e-05	0.000469	CcSEcCtD
Alitretinoin—Decreased appetite—Methotrexate—bone cancer	5.92e-05	0.000467	CcSEcCtD
Alitretinoin—Anaphylactic shock—Doxorubicin—bone cancer	5.9e-05	0.000465	CcSEcCtD
Alitretinoin—Oedema—Doxorubicin—bone cancer	5.9e-05	0.000465	CcSEcCtD
Alitretinoin—Gastrointestinal disorder—Methotrexate—bone cancer	5.88e-05	0.000464	CcSEcCtD
Alitretinoin—Fatigue—Methotrexate—bone cancer	5.87e-05	0.000463	CcSEcCtD
Alitretinoin—Infection—Doxorubicin—bone cancer	5.86e-05	0.000462	CcSEcCtD
Alitretinoin—Pain—Methotrexate—bone cancer	5.82e-05	0.000459	CcSEcCtD
Alitretinoin—Musculoskeletal discomfort—Epirubicin—bone cancer	5.81e-05	0.000458	CcSEcCtD
Alitretinoin—Shock—Doxorubicin—bone cancer	5.8e-05	0.000457	CcSEcCtD
Alitretinoin—Nervous system disorder—Doxorubicin—bone cancer	5.78e-05	0.000456	CcSEcCtD
Alitretinoin—Thrombocytopenia—Doxorubicin—bone cancer	5.77e-05	0.000455	CcSEcCtD
Alitretinoin—Insomnia—Epirubicin—bone cancer	5.77e-05	0.000454	CcSEcCtD
Alitretinoin—Tachycardia—Doxorubicin—bone cancer	5.76e-05	0.000454	CcSEcCtD
Alitretinoin—Skin disorder—Doxorubicin—bone cancer	5.73e-05	0.000452	CcSEcCtD
Alitretinoin—Paraesthesia—Epirubicin—bone cancer	5.72e-05	0.000451	CcSEcCtD
Alitretinoin—Hyperhidrosis—Doxorubicin—bone cancer	5.7e-05	0.000449	CcSEcCtD
Alitretinoin—Dyspnoea—Epirubicin—bone cancer	5.68e-05	0.000448	CcSEcCtD
Alitretinoin—Somnolence—Epirubicin—bone cancer	5.67e-05	0.000447	CcSEcCtD
Alitretinoin—CYP1A2—Arachidonic acid metabolism—PTGS2—bone cancer	5.66e-05	0.000708	CbGpPWpGaD
Alitretinoin—Anorexia—Doxorubicin—bone cancer	5.62e-05	0.000443	CcSEcCtD
Alitretinoin—Feeling abnormal—Methotrexate—bone cancer	5.61e-05	0.000442	CcSEcCtD
Alitretinoin—RXRA—Gene Expression—NR1I2—bone cancer	5.61e-05	0.000702	CbGpPWpGaD
Alitretinoin—Dyspepsia—Epirubicin—bone cancer	5.61e-05	0.000442	CcSEcCtD
Alitretinoin—Gastrointestinal pain—Methotrexate—bone cancer	5.57e-05	0.000439	CcSEcCtD
Alitretinoin—Decreased appetite—Epirubicin—bone cancer	5.54e-05	0.000437	CcSEcCtD
Alitretinoin—Hypotension—Doxorubicin—bone cancer	5.51e-05	0.000434	CcSEcCtD
Alitretinoin—Gastrointestinal disorder—Epirubicin—bone cancer	5.5e-05	0.000434	CcSEcCtD
Alitretinoin—Fatigue—Epirubicin—bone cancer	5.5e-05	0.000433	CcSEcCtD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	5.48e-05	0.000685	CbGpPWpGaD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	5.48e-05	0.000685	CbGpPWpGaD
Alitretinoin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	5.46e-05	0.000683	CbGpPWpGaD
Alitretinoin—Constipation—Epirubicin—bone cancer	5.45e-05	0.00043	CcSEcCtD
Alitretinoin—Pain—Epirubicin—bone cancer	5.45e-05	0.00043	CcSEcCtD
Alitretinoin—Urticaria—Methotrexate—bone cancer	5.41e-05	0.000427	CcSEcCtD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	5.4e-05	0.000676	CbGpPWpGaD
Alitretinoin—Abdominal pain—Methotrexate—bone cancer	5.38e-05	0.000424	CcSEcCtD
Alitretinoin—Body temperature increased—Methotrexate—bone cancer	5.38e-05	0.000424	CcSEcCtD
Alitretinoin—Musculoskeletal discomfort—Doxorubicin—bone cancer	5.37e-05	0.000424	CcSEcCtD
Alitretinoin—Insomnia—Doxorubicin—bone cancer	5.33e-05	0.00042	CcSEcCtD
Alitretinoin—Paraesthesia—Doxorubicin—bone cancer	5.3e-05	0.000417	CcSEcCtD
Alitretinoin—Dyspnoea—Doxorubicin—bone cancer	5.26e-05	0.000414	CcSEcCtD
Alitretinoin—Feeling abnormal—Epirubicin—bone cancer	5.25e-05	0.000414	CcSEcCtD
Alitretinoin—Somnolence—Doxorubicin—bone cancer	5.24e-05	0.000413	CcSEcCtD
Alitretinoin—Gastrointestinal pain—Epirubicin—bone cancer	5.21e-05	0.000411	CcSEcCtD
Alitretinoin—Dyspepsia—Doxorubicin—bone cancer	5.19e-05	0.000409	CcSEcCtD
Alitretinoin—Decreased appetite—Doxorubicin—bone cancer	5.13e-05	0.000404	CcSEcCtD
Alitretinoin—ABCB1—HIF-1-alpha transcription factor network—JUN—bone cancer	5.12e-05	0.000641	CbGpPWpGaD
Alitretinoin—Gastrointestinal disorder—Doxorubicin—bone cancer	5.09e-05	0.000401	CcSEcCtD
Alitretinoin—Fatigue—Doxorubicin—bone cancer	5.08e-05	0.000401	CcSEcCtD
Alitretinoin—Urticaria—Epirubicin—bone cancer	5.06e-05	0.000399	CcSEcCtD
Alitretinoin—Pain—Doxorubicin—bone cancer	5.04e-05	0.000398	CcSEcCtD
Alitretinoin—Constipation—Doxorubicin—bone cancer	5.04e-05	0.000398	CcSEcCtD
Alitretinoin—Abdominal pain—Epirubicin—bone cancer	5.04e-05	0.000397	CcSEcCtD
Alitretinoin—Body temperature increased—Epirubicin—bone cancer	5.04e-05	0.000397	CcSEcCtD
Alitretinoin—Hypersensitivity—Methotrexate—bone cancer	5.02e-05	0.000396	CcSEcCtD
Alitretinoin—Asthenia—Methotrexate—bone cancer	4.89e-05	0.000385	CcSEcCtD
Alitretinoin—Feeling abnormal—Doxorubicin—bone cancer	4.86e-05	0.000383	CcSEcCtD
Alitretinoin—Gastrointestinal pain—Doxorubicin—bone cancer	4.82e-05	0.00038	CcSEcCtD
Alitretinoin—Pruritus—Methotrexate—bone cancer	4.82e-05	0.00038	CcSEcCtD
Alitretinoin—CYP1A2—Biological oxidations—CYP3A4—bone cancer	4.76e-05	0.000595	CbGpPWpGaD
Alitretinoin—Hypersensitivity—Epirubicin—bone cancer	4.7e-05	0.00037	CcSEcCtD
Alitretinoin—CYP1A2—Metapathway biotransformation—CYP3A4—bone cancer	4.69e-05	0.000587	CbGpPWpGaD
Alitretinoin—Urticaria—Doxorubicin—bone cancer	4.69e-05	0.000369	CcSEcCtD
Alitretinoin—Abdominal pain—Doxorubicin—bone cancer	4.66e-05	0.000368	CcSEcCtD
Alitretinoin—Body temperature increased—Doxorubicin—bone cancer	4.66e-05	0.000368	CcSEcCtD
Alitretinoin—Diarrhoea—Methotrexate—bone cancer	4.66e-05	0.000367	CcSEcCtD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	4.58e-05	0.000573	CbGpPWpGaD
Alitretinoin—Asthenia—Epirubicin—bone cancer	4.57e-05	0.00036	CcSEcCtD
Alitretinoin—ABCB1—Transmembrane transport of small molecules—TUBB4B—bone cancer	4.57e-05	0.000571	CbGpPWpGaD
Alitretinoin—Pruritus—Epirubicin—bone cancer	4.51e-05	0.000355	CcSEcCtD
Alitretinoin—Dizziness—Methotrexate—bone cancer	4.5e-05	0.000355	CcSEcCtD
Alitretinoin—Diarrhoea—Epirubicin—bone cancer	4.36e-05	0.000344	CcSEcCtD
Alitretinoin—Hypersensitivity—Doxorubicin—bone cancer	4.35e-05	0.000343	CcSEcCtD
Alitretinoin—Vomiting—Methotrexate—bone cancer	4.33e-05	0.000341	CcSEcCtD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	4.31e-05	0.000539	CbGpPWpGaD
Alitretinoin—Rash—Methotrexate—bone cancer	4.29e-05	0.000339	CcSEcCtD
Alitretinoin—Dermatitis—Methotrexate—bone cancer	4.29e-05	0.000338	CcSEcCtD
Alitretinoin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	4.29e-05	0.000537	CbGpPWpGaD
Alitretinoin—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—bone cancer	4.29e-05	0.000537	CbGpPWpGaD
Alitretinoin—Headache—Methotrexate—bone cancer	4.27e-05	0.000336	CcSEcCtD
Alitretinoin—Asthenia—Doxorubicin—bone cancer	4.23e-05	0.000334	CcSEcCtD
Alitretinoin—Dizziness—Epirubicin—bone cancer	4.22e-05	0.000332	CcSEcCtD
Alitretinoin—Pruritus—Doxorubicin—bone cancer	4.17e-05	0.000329	CcSEcCtD
Alitretinoin—RXRA—Gene Expression—EIF2S1—bone cancer	4.14e-05	0.000518	CbGpPWpGaD
Alitretinoin—CYP1A2—Biological oxidations—GSTP1—bone cancer	4.07e-05	0.000509	CbGpPWpGaD
Alitretinoin—Vomiting—Epirubicin—bone cancer	4.05e-05	0.000319	CcSEcCtD
Alitretinoin—Nausea—Methotrexate—bone cancer	4.05e-05	0.000319	CcSEcCtD
Alitretinoin—Diarrhoea—Doxorubicin—bone cancer	4.04e-05	0.000318	CcSEcCtD
Alitretinoin—Rash—Epirubicin—bone cancer	4.02e-05	0.000317	CcSEcCtD
Alitretinoin—Dermatitis—Epirubicin—bone cancer	4.02e-05	0.000317	CcSEcCtD
Alitretinoin—CYP1A2—Metapathway biotransformation—GSTP1—bone cancer	4.01e-05	0.000502	CbGpPWpGaD
Alitretinoin—Headache—Epirubicin—bone cancer	3.99e-05	0.000315	CcSEcCtD
Alitretinoin—RXRA—Developmental Biology—MET—bone cancer	3.97e-05	0.000497	CbGpPWpGaD
Alitretinoin—RXRA—Developmental Biology—CDK4—bone cancer	3.97e-05	0.000497	CbGpPWpGaD
Alitretinoin—ABCB1—Transmembrane transport of small molecules—TUBB2A—bone cancer	3.94e-05	0.000493	CbGpPWpGaD
Alitretinoin—Dizziness—Doxorubicin—bone cancer	3.9e-05	0.000307	CcSEcCtD
Alitretinoin—Nausea—Epirubicin—bone cancer	3.79e-05	0.000298	CcSEcCtD
Alitretinoin—Vomiting—Doxorubicin—bone cancer	3.75e-05	0.000296	CcSEcCtD
Alitretinoin—CRABP1—Metabolism—PTGS2—bone cancer	3.73e-05	0.000467	CbGpPWpGaD
Alitretinoin—CRABP2—Metabolism—PTGS2—bone cancer	3.73e-05	0.000467	CbGpPWpGaD
Alitretinoin—Rash—Doxorubicin—bone cancer	3.72e-05	0.000293	CcSEcCtD
Alitretinoin—Dermatitis—Doxorubicin—bone cancer	3.72e-05	0.000293	CcSEcCtD
Alitretinoin—Headache—Doxorubicin—bone cancer	3.69e-05	0.000291	CcSEcCtD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	3.61e-05	0.000452	CbGpPWpGaD
Alitretinoin—RXRA—Gene Expression—EZH2—bone cancer	3.6e-05	0.00045	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—NDUFA12—bone cancer	3.57e-05	0.000447	CbGpPWpGaD
Alitretinoin—Nausea—Doxorubicin—bone cancer	3.5e-05	0.000276	CcSEcCtD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	3.4e-05	0.000425	CbGpPWpGaD
Alitretinoin—RXRA—Developmental Biology—MMP2—bone cancer	3.31e-05	0.000415	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—ENO2—bone cancer	3.24e-05	0.000406	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—DHFR—bone cancer	3.01e-05	0.000376	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—NT5C3A—bone cancer	2.96e-05	0.00037	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—NDUFA12—bone cancer	2.85e-05	0.000357	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—GNA11—bone cancer	2.81e-05	0.000352	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—CYP3A4—bone cancer	2.55e-05	0.000319	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.54e-05	0.000317	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	2.52e-05	0.000315	CbGpPWpGaD
Alitretinoin—RXRA—Developmental Biology—MMP9—bone cancer	2.49e-05	0.000312	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	2.43e-05	0.000304	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—NT5C3A—bone cancer	2.36e-05	0.000295	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	2.19e-05	0.000274	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—GSTP1—bone cancer	2.18e-05	0.000273	CbGpPWpGaD
Alitretinoin—RXRA—Developmental Biology—EGFR—bone cancer	2.01e-05	0.000252	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	1.72e-05	0.000215	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	1.44e-05	0.000181	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—ENO2—bone cancer	1.3e-05	0.000162	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—DHFR—bone cancer	1.2e-05	0.00015	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—PTGS2—bone cancer	1.13e-05	0.000141	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—GNA11—bone cancer	1.12e-05	0.000141	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—ENO2—bone cancer	1.03e-05	0.000129	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—CYP3A4—bone cancer	1.02e-05	0.000127	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—DHFR—bone cancer	9.6e-06	0.00012	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—GNA11—bone cancer	8.97e-06	0.000112	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—GSTP1—bone cancer	8.71e-06	0.000109	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—CYP3A4—bone cancer	8.13e-06	0.000102	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	8.09e-06	0.000101	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—GSTP1—bone cancer	6.96e-06	8.7e-05	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—PTGS2—bone cancer	4.51e-06	5.65e-05	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—PTGS2—bone cancer	3.6e-06	4.51e-05	CbGpPWpGaD
